Navigation Links
Haemacure Update on Proposed Collaboration and Bridge Financing
Date:5/22/2009

satisfied, that the transaction will close, or that Haemacure will effect an equity financing of at least US$13.5 million.

Assuming: (i) the conversion into Haemacure common shares by Angiotech of the principal amount of the loan and interest in an aggregate amount of US$3.67 million; (ii) an exchange rate of $1.20 for each U.S. dollar; (iii) an issue price of $0.05 in an equity financing by Haemacure in the amount of US$13.5 million; and (iv) full exercise of the warrant by Angiotech, Haemacure would issue an aggregate of 191,703,529 additional common shares to Angiotech, representing 26.55% of the 722,019,827 shares that would then be issued and outstanding, and 92.91% of the 206,316,298 shares currently outstanding.

As the aggregate number of common shares that may be issued upon the conversion of the loan and exercise of the warrant, if any, by Angiotech may exceed 25% of the number of Haemacure shares currently outstanding (206,316,298) and materially affect control of Haemacure, and due to the fact that the conversion price of the loan and exercise price of the warrant may not be in compliance with the applicable pricing policies of the TSX, the transaction requires shareholder approval under the TSX Company Manual. Haemacure is relying on an exemption from the security-holder approval requirements granted by the Toronto Stock Exchange under section 604(e) of the TSX Company Manual, on the basis of serious financial difficulty. The directors of Haemacure have determined that Haemacure is in serious financial difficulty and that the senior secured bridge loan of US$2.5 million from Angiotech is designed to improve Haemacure's financial situation. Upon a recommendation from an independent committee of the Board of Directors of Haemacure free from any interest in the transaction and unrelated to Angiotech, the Board of Directors has also determined that the senior secured bridge loan is reasonable for Haemacure in the circumstances.

The T
'/>"/>

SOURCE Haemacure Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Haemacure Signs Term Sheet for Proposed Collaboration and Bridge Financing
2. Haemacure Reports First Quarter 2009 Results and Hires Advisor for the Sale or Merger of the Company
3. Haemacure Restructures - Seeks Financing or Sale of the Company
4. Haemacure to Present at the 11th Annual BIO CEO & Investor Conference
5. Haemacure Announces Fiscal 2008 Results
6. Haemacures Human Fibrin Sealant Demonstrates Effectiveness in Skin Graft Fixation Proof-of-Concept Study for Burn Injury
7. Haemacure Confirms Operation Qualification of Production Equipment and Pursues Milestone Payment from CSL
8. Haemacure to Present at the Rodman & Renshaw Annual Global Investor Conference
9. Haemacure Appoints Thomas J. Lynch, J.D., Ph.D. to Board of Directors
10. Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model
11. Haemacure Raises $7.8 Million and is Fully Funded Beyond First-Patient-In-Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... ... , ... The condition where veins are enlarged and gnarled is known as ... discomfort. Those who spend a lot of time on their feet and standing are ... what it can to create awareness and provide a cure in observance of Senior ...
(Date:8/1/2015)... New York, NY (PRWEB) , ... August 01, 2015 , ... ... Black Vine cyberespionage group , who are thought to have been behind the attack ... Among the topics covered were zero day exploits, watering hole attacks and spear phishing ...
(Date:7/31/2015)... ... July 31, 2015 , ... That’s ... What are the STASH awards? The Significant Technological Achievements in Secretive Horticulture (or ... as well as tried-and-true products that have stood the test of time. These ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source ... in Chicago at Grant Park. The festival will end on Sunday, August 2nd. ... Chicago for the annual Lollapalooza. This unique and unbelievably popular festival attracts the ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Sculpted Contours Luxury ... CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator in the United ... 2014 for treating the outer thighs. The original applicator required a 2 hour ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... to Receive Full Benefits After Retirement, WASHINGTON, ... employer-sponsored retirement plans, retiree,medical plans or other financial ... Security or Medicare payments after they retire. Confidence ... female or have a,lower level of education, according ...
... Weston Medical Publishing today,announced publication ... of Neurodegeneration,and Regeneration. (ISSN 1932-1481) This ... all aspects of neurodegeneration, neuroprotection and,neuroregeneration ... their relevance in treating neurodegenerative disorders ...
... 2008, New York, NYA new report from The Commonwealth ... the health system reform proposals of presidential candidates Senator ... The 2008 Presidential Candidates, Health Reform Proposals: Choices for ... expand health insurance, but Senator McCain would encourage individuals ...
... 1 The Agency for,Healthcare Research and Quality ... help reduce central line-associated bloodstream infections in,hospital intensive ... from,a previous AHRQ-funded project. The Health Research & ... has been selected to,coordinate the new 3-year project, ...
... Highly Successful MHA Keystone: ICU Patient Safety Program, ... for Healthcare,Research and Quality (AHRQ) today announced a ... of hospital-associated infections,in intensive care units (ICUs)., ... efforts,of the Michigan Health & Hospital Association,s (MHA) ...
... Oct. 1 BioForm Medical,Inc. (Nasdaq: BFRM ) ... the,2008 Maxim Group Growth Conference on Tuesday, October 7, ... scheduled to,provide a corporate overview of the Company at ... portion of the presentation will be webcast live and ...
Cached Medicine News:Health News:Older Workers Worried About Promised Medicare and Social Security Benefits, Watson Wyatt Survey Finds 2Health News:Older Workers Worried About Promised Medicare and Social Security Benefits, Watson Wyatt Survey Finds 3Health News:New Journal to Explore Neurodegenerative, Neuroprotective and Euroregenerative Therapies! 2Health News:Presidential candidates' health plans offer divergent approaches to health system reform 2Health News:Presidential candidates' health plans offer divergent approaches to health system reform 3Health News:Presidential candidates' health plans offer divergent approaches to health system reform 4Health News:AHRQ Awards $3 Million to Help Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs 2Health News:Michigan Success Lands National Research Contract to Reduce Hospital-Associated Infections in 10 States 2Health News:BioForm Medical to Present at the 2008 Maxim Group Growth Conference 2
(Date:7/31/2015)... N.J. and SAN DIEGO ... that its parent company Eisai Co., Ltd. (Headquarters: ... Naito , "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: ... Dr. Helen Torley , "NASDAQ: HALO") have signed ... (brand name: Halaven ® , "eribulin") in combination with ...
(Date:7/31/2015)... July 31, 2015 According to ... by Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), ... - Global Analysis & Forecast to 2019", published by ... at $911.1 Million 2014 and is estimated to grow ... of 9.4% from 2014 to 2019. ...
(Date:7/30/2015)... , July 30, 2015 Edwards Lifesciences Corporation ... of heart valves and hemodynamic monitoring, today announced that ... of Directors. "Bob is an ardent champion for ... true privilege to have him on Edwards, board as we ... , Edwards, chairman and CEO.  "Bob has provided a valuable ...
Breaking Medicine Technology:Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
... YORK, Feb. 6, 2012 Reportlinker.com announces ... available in its catalogue: , ... Antivirals) http://www.reportlinker.com/p0769020/World-Market-for-Anti-Infectives-Antifungals-Antibacterials-and-Antivirals- ... Information report – The World Market ...
... Conn., Feb. 3, 2012 Boehringer Ingelheim presented ... Aggrenox® (aspirin/extended-release dipyridamole), an antiplatelet medication, is not ... pump inhibitor (PPI), frequently used to treat several ... International Stroke Conference (ISC) in New Orleans. ...
Cached Medicine Technology:World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 2World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 3World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 4World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 5World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 6World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 7World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 8World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 9Study Finds No Drug-Drug Interaction Between Aggrenox® (aspirin/extended-release dipyridamole) 25mg/200mg Capsules and Omeprazole, a Widely Used PPI 2Study Finds No Drug-Drug Interaction Between Aggrenox® (aspirin/extended-release dipyridamole) 25mg/200mg Capsules and Omeprazole, a Widely Used PPI 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: